Category: Novel Drug Delivery
Novel Drug Delivery
Delcath Systems Inc. brings in $33.8 million in a public offering of 5.2 million shares.
After raking in $33.8 million, Delcath Systems Inc. (NSDQ:DCTH) closed its public offering of 5.2 million shares.
According to a Securities & Exchange Commission filing, the New York-based company plans to use the proceeds from the sale to fund "clinical trials, research & development, obtaining regulatory approvals, manufacturing, operations, sales, commercialization of its products and other general corporate purposes including capital expenditures and working capital."
Echo Therapeutics Inc. and Ferndale Pharma Group Inc. enroll the first patients in a clinical trial of Echo's Prelude SkinPrep device and Ferndale's over-the-counter topical lidocaine as they gear up for a 510(k) clearance application with the Food & Drug Administration.
Echo Therapeutics Inc. (OTC:ECTE) and Ferndale Pharma Group Inc. enrolled the first patients in a clinical trial of Echo's Prelude SkinPrep device and Ferndale's 4 percent topical lidocaine, ahead of an application for 510(k) clearance for the drug-device combo from the Food & Drug Administration.
Franklin, Mass.-based Echo's Prelude device is a needle-free, transdermal drug delivery system that ablates a thin layer of skin before a drug is applied.
Providence, R.I-based drug delivery patch developer Isis Biopolymer Inc. brings in another $3 million from an equity sale.
Isis Biopolymer Inc., a company developing a new generation of non-invasive drug delivery patches, has raised $3 million through an equity sale to existing investors.
The Providence, R.I.-based firm has developed the Isis Patch, a compact, wireless, active iontophoretic patch using a design that implements advances in microprocessors, thin film batteries, biopolymers and adhesives.
In a statement sent to MassDevice, CEO Emma Durand said the current round "clearly shows the confidence of the investment community in Isis Biopolymer and our innovative transdermal drug delivery and biosensor technology."
Echo Therapeutics' development work on its Prelude SkinPrep system for transdermal drug delivery is finished and clinical trials of its efficacy in delivering lidocaine are imminent.
Echo Therapeutics Inc. (OTC:ECTE) reached a milestone with one of its two flagship products, the Prelude SkinPrep system, which is ready for clinical trials examining its use in dispensing lidocaine.
The Franklin, Mass.-based company, which is also developing a needle-free glucose monitoring system called the Symphony tCGM, said its development work on the Prelude system is complete and it's ready for a study in the "near term."
Bedford, Mass. based drug delivery systems company one of 26 honored as technology pioneers by Swiss think tank
What does MicroCHIPS Inc. have in common with Twitter?
Both were among a pool of 26 firms named 2010 Technology Pioneers by the World Economic Forum in Switzerland. The awards are handed out yearly to companies that are "involved in the development of a life-changing technology innovation and have the potential for long-term impact on business and society."
The 26 companies were winnowed from a pool of 300 applicants and judged by 58 "experts," according to the Swiss think tank, from the ranks of academia, media and industry.
The Franklin, Mass.-based glucose monitor maker says it will release the results of its Symphony tCGM Biosensor study during the fourth quarter.
Echo Therapeutics Inc. will complete a clinical study of its Symphony non-invasive, wireless transdermal continuous glucose monitoring system by the fourth quarter, in what would be a major step forward for a company that has burned through more than $60 million trying to bring its products to market.
(401) 921-6868
(401) 921-6873 (FAX)
Product(s):
Developing the Isis Patch, a compact, wireless, active iontophoretic patch using a design that implements advances in microprocessors, thin film batteries, biopolymers and adhesives.
President:
Emma A. Durand
Management:
Shawna Gvazdauskas, Chief Commercial Officer
Michael Jordan, Director of Product Development